Umaimah Naeem

Dr. Umaimah Naeem

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
HMHaleema Mansoor
Haleema Mansoor
MGMaheen Gohar
Maheen Gohar
AAAsma Attaria
Asma Attaria
FKFaiza Fatima Karim
Faiza Fatima Karim
UNUmaimah Naeem
Umaimah Naeem
JIJaved Iqbal
Javed Iqbal
Gastric cancer, especially cancer of the gastro-esophageal junction, ranks among the first five cancers in the world with the highest mortality rates. It has poor survival rates for the advanced stages. Traditional chemotherapy, while standard, often results in significant side effects and limited efficacy. The objective of this meta-analysis and systemic review is to ascertain if pembrolizumab-based therapies for advanced gastric cancer are more effective and safer than standard chemotherapy. The focus consisted of RCTs with adults suffering from gastric carcinoma who received pembrolizumab every 3 weeks (200 mg) intra-related dose or with at least comparable chemotherapy regimen. Outcomes assessed are as follows: overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). All potential sources regarding the search of outcome measures were applied: Google Scholar, Scopus, PubMed, and Cochrane library, and last search in June 2024 was carried out. Out of 568 articles screened, four RCTs comprising 2,831 patients met the inclusion criteria. Analysis indicated that pembrolizumab alone did not significantly improve OS compared to chemotherapy (HR 0.87). However, when combined with chemotherapy, pembrolizumab dramatically enhanced OS (HR 0.80) and PFS (HR 0.78). ORR was superior in the pembrolizumab plus chemotherapy group (RR 1.24), while pembrolizumab monotherapy showed no significant difference from chemotherapy alone. Safety analysis revealed a higher frequency of adverse events in the pembrolizumab-based therapy groups compared to chemotherapy. Pembrolizumab together with chemotherapy improves greater survival and higher levels of response rate in patients with severe gastric cancer, especially with high PD-L1 expression. But it has rather more adverse events, allowing patient monitoring with care.

1 December 2025 in Microbiologyopen
Verified
Journal Article
Open access
AAAsma Azam
Asma Azam
MQMuhammad Abdul Muqtadir Qureshi
Muhammad Abdul Muqtadir Qureshi
HZHafiz Shahbaz Zahoor
Hafiz Shahbaz Zahoor
SRSyeda Malaika Raza
Syeda Malaika Raza
MKMuhammad Mohsin Khan
Muhammad Mohsin Khan
AWAbdul Waheed
Abdul Waheed
Supplementing H. pylori treatment with probiotics like Lactobacillus has become an essential approach due to the possible adverse effects of antibiotic therapy and the need to increase overall eradication rates. Although several types of Lactobacillus strains as probiotics were efficient in treating H. pylori , their relative efficiency in treating H. pylori was uncertain. A survey of databases, including PubMed, Cochrane, Google Scholar, Scopus, and Clinicaltrials.gov , retrieved 52 Randomized Controlled Trials (RCTs), with 14 meeting the criteria for RCTs on Lactobacillus supplementation (LS) as an adjunct therapy compared to placebo in adult H. pylori patients. Analyses were conducted using RevMan5.3, Cochrane Risk of Bias Tool, Comprehensive Meta‐Analysis Software, and GRADEpro. Fourteen RCTs, including 2054 patients with more than ten different probiotics, were included in this analysis. The LS group showed significantly higher H. pylori eradication rates [RR = 1.04 (95% CI: 1.01, 1.07; p = 0.009; I 2 = 0%); (high certainty)], decreased AEs including vomiting [RR = 0.82 (95% CI: 0.48, 1.41; p = 0.48; I 2 = 19%); (high certainty)], diarrhea [RR = 0.45 (95% CI: 0.26, 0.80; p = 0.007; I ² = 55%); (high certainty)], abdominal pain [RR = 0.73 (95% CI: 0.28, 1.93; p = 0.53; I ² = 66%); (high certainty)], anorexia [RR = 0.79 (95% CI: 0.23, 2.64; p = 0.70; I ² = 0%); (high certainty)], constipation [RR = 1.02 (95% CI: 0.42, 2.50; p = 0.96; I ² = 0%); (high certainty)], rash [RR = 1.51 (95% CI: 0.57, 3.98; p = 0.41; I ² = 0%); (high certainty)], taste disturbance [RR = 0.64 (95% CI: 0.44, 0.92; p = 0.02; I ² = 51%); (moderate certainty)], and reduction of gastrointestinal symptoms including abdominal pain [SMD = −0.19 (95% CI: −0.46, 0.09; p = 0.18; I² = %); (moderate certainty)]. None of the included RCTs depicted a high risk of bias. Lactobacillus added to triple or quadruple therapy increased eradication rates, but improvements in adverse effects and gastrointestinal symptoms were not significant. Multiple different strains limited assessment of individual effectiveness, preventing firm conclusions about the specific impact of each Lactobacillus type.

12 November 2025 in Therapeutic Advances in Cardiovascular Disease
Verified
Journal Article
Open access
MSMaha Sajjad
Maha Sajjad
RARabia Ashraf
Rabia Ashraf
RBRiya Bhagwan
Riya Bhagwan
HIHassan Ijaz
Hassan Ijaz
AEAyesha Ejaz
Ayesha Ejaz
AAAizaz Ali
Aizaz Ali
Background: Hereditary transthyretin amyloidosis (hATTR) is caused by mutations in the transthyretin (TTR) gene, which lead to the aggregation of misfolded TTR protein and amyloid accumulation in the peripheral nerves, heart, and gastrointestinal tract. Recently, RNA therapeutics, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have been approved for treating patients with hATTR. Objectives: To assess the neurological efficacy and safety of RNA therapeutics in hATTR patients. Design: Systematic review and meta-analysis. Data sources and methods: A systematic literature search was conducted on PubMed, Cochrane, and ClinicalTrials.gov from inception to August 14, 2024. Outcomes included changes from baseline in the Norfolk Quality of Life–Diabetic Neuropathy (Norfolk QOL-DN) score and the modified Neuropathy Impairment Score +7 (mNIS + 7), modified body mass index (mBMI), adverse effects, serious adverse events, and all-cause mortality. Results: Our study included four RCTs with 842 patients (568 in the RNA therapeutics group and 274 in the placebo group). RNA therapeutics significantly improved Norfolk QoL-DN (mean difference (MD), −18.79; 95% CI, −22.32 to −15.25; p < 0.00001; I 2 = 28%) and mNIS + 7 scores (MD, −26.90; 95% CI, −31.67 to −22.13; p < 0.00001; I 2 = 61%), with significant preservation of mBMI (MD, 114.98; 95% CI, 90.64–139.32; p < 0.00001; I 2 = 59%) compared to placebo. There were no significant differences between the two groups regarding the risk of adverse effects (risk ratio (RR), 0.89; 95% CI, 0.69–1.15; p = 0.36; I 2 = 34%), serious adverse effects (RR, 0.70; 95% CI, 0.31–1.58; p = 0.39; I 2 = 20%), and all-cause mortality (RR, 0.70; 95% CI, 0.31 to 1.58; p = 0.39; I 2 = 20%). Conclusion: RNA therapeutics are effective and well-tolerated in patients with hATTR, significantly improving quality of life and the progression of neurological impairment. siRNAs demonstrate better outcomes compared to ASOs. Trial registration: PROSPERO (CRD42024568346).

5 June 2025 in Therapeutic Advances in Vaccines and Immunotherapy
Verified
Journal Article
Open access
ESErum Siddiqui
Erum Siddiqui
MKMohammad Saad Khan
Mohammad Saad Khan
MKMaliha Khalid
Maliha Khalid
HCHarshika Khaim Chandani
Harshika Khaim Chandani
UNUmaimah Naeem
Umaimah Naeem
SWSyed Owais Wasti
Syed Owais Wasti
Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is an ancient disease that continues to pose a significant threat to global public health. Although the BCG vaccine, developed in the 1920s, remains the only approved TB vaccine, it has limited efficacy, particularly against pulmonary TB in adults. The ID93/GLA-SE vaccine, a recombinant subunit vaccine, shows promise by triggering immune solid responses and could be a key solution in combating TB, particularly in the face of rising drug-resistant strains and suboptimal current vaccines. It has the potential to address the unmet need for more effective interventions against drug-resistant TB, a growing global health issue that continues to challenge existing treatment options. Objective: To evaluate the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults. Methods: A comprehensive electronic search on PubMed (Medline), ScienceDirect, EMBASE, Scopus, and Cochrane Central database was conducted from inception till August 2024 for randomized controlled trials (RCTs) with a target population of BCG-vaccinated healthy adults. This review was conducted according to (PRISMA) criteria and registered with PROSPERO (CRD42024601450). This meta-analysis used Review Manager and forest plots for visual display. The outcomes were displayed as risk ratios (RR) with a 95% confidence interval. Results: The ID93 + GLA-SE vaccine showed strong immunogenicity, particularly in high doses, with robust IgG responses sustained up to day 421 in all studies, significantly higher than baseline, and seroconversion rates remained high through day 84. CD4 T-cell responses peaked after the third dose and remained elevated through day 421, whereas CD8 T-cell responses were minimal. Regarding adverse effects, the ID93 + GLA-SE vaccine significantly increases fatigue (RR 3.24, p = 0.005), myalgia (RR 5.82, p < 0.0001), and injection site pain (RR 4.12, p < 0.00001), compared to placebo, with consistent results across both high and low doses. However, there were no significant differences for upper respiratory tract infections, 0.83 (95% CI 0.38–1.84, p = 0.87) or 1.77 (95% CI 0.77–4.10, p = 0.18) headaches. Dose optimization remains crucial due to the higher side effect risks of increased doses. Conclusion: The ID93 + GLA-SE vaccine shows a solid safety profile and enhances immune responses, especially IgG and CD4+ T-cell activity, which is crucial for TB defense. Higher doses improve efficacy but increase side effects, highlighting the need for dose optimization. As a potential alternative to the BCG vaccine, especially in drug-resistant TB regions, further research should refine dosage and assess long-term safety.

1 August 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
AKAmna Kamil
Amna Kamil
SKSandhiya Prem Kumar
Sandhiya Prem Kumar
RZRumaisa Zulfiqar
Rumaisa Zulfiqar
EAEiman Araib
Eiman Araib
BKBibi Samia Khan
Bibi Samia Khan
AWAminath Waafira
Aminath Waafira
Background: Cancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population. While traditional anticoagulants like low-molecular-weight heparin (LMWH) and vitamin K antagonists (VKAs) are commonly used, their limitations have prompted growing interest in direct oral anticoagulants (DOACs), particularly Factor Xa inhibitors. However, concerns about bleeding risks persist. This meta-analysis aims to evaluate the efficacy of Factor Xa inhibitors versus placebo for thromboprophylaxis in cancer-associated VTE. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was registered with PROSPERO (CRD42024574869). A comprehensive search of PubMed, Cochrane Library, Scopus, Google Scholar, and ClinicalTrials.gov was conducted without language or demographic restrictions. Data were extracted independently by two reviewers and analyzed using a random-effects model. Results: Six RCTs with a total of 2330 participants met the inclusion criteria. The pooled analysis showed a non-significant reduction in VTE incidence with Factor Xa inhibitors (RR = 0.33, 95% CI: 0.05-2.10, P = .24). However, there was a nearly twofold increased risk of major bleeding (RR = 1.90, 95% CI: 1.00-3.62, P = .05). No significant effect was found for clinically relevant non-major bleeding (CRNMB) (RR = 1.28, 95% CI: 0.73-2.22, P = .39). Conclusion: Factor Xa inhibitors may reduce the risk of VTE in cancer patients but appear to increase the risk of major bleeding. The evidence remains inconclusive due to limited event numbers and wide confidence intervals, highlighting the need for larger trials to better assess safety and efficacy.

25 February 2026 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
UNUmaimah Naeem
Umaimah Naeem
HZHafiza Fatima Zahid
Hafiza Fatima Zahid
SISarah Imtiaz
Sarah Imtiaz
QKQuratulain Khan
Quratulain Khan
AIAmmara Iftikhar
Ammara Iftikhar
KSKalpana Singh
Kalpana Singh
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare interstitial lung disease characterized by surfactant accumulation within alveoli due to impaire